The development of next generation TKIs addresses several limitations associated with first-generation TKIs, including drug resistance, off-target effects, and limited efficacy against certain cancer types. These advanced inhibitors are designed to be more selective, potent, and capable of overcoming resistance mechanisms, making them a critical advancement in the personalized treatment of cancer.
